Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pulse BiosciencesPLSE +2.31%31 12-1 Month Momentum % is 88.26% as of Jul. 31, 2026. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 824 Medical Devices & Instruments companies, Pulse Biosciences ranks better than 95.39% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-31), Pulse Biosciences's 12-1 Month Momentum % is 88.26%.
The industry rank for Pulse Biosciences's 12-1 Month Momentum % or its related term are showing as below:
PLSE's 12-1 Month Momentum % is ranked better than 95.39% of 824
companies
in the Medical Devices & Instruments industry
Industry Median: -18.655
vs PLSE: 88.26
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Pulse Biosciences 12-1 Month Momentum % Related Terms
PLSE vs LMAT, ATRC, XRAY: 12-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences 12-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences (PLSE) has a 12-1 Month Momentum % of 88.26% as of Jul. 31, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Pulse Biosciences and its competitors. According to the industry distribution chart, Pulse Biosciences ranks #38 out of 824 companies in the Medical Devices & Instruments industry, placing it in the top 4.6%.
Is Pulse Biosciences' 12-1 Month Momentum % too high?
Pulse Biosciences' current 12-1 Month Momentum % is 88.26%. Based on the distribution chart, Pulse Biosciences ranks #38 out of 824 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' 12-1 Month Momentum % compare to LMAT and ATRC?
According to the Medical Devices & Instruments industry distribution chart, Pulse Biosciences ranks #38 out of 824 companies for 12-1 Month Momentum %. This places Pulse Biosciences in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Pulse Biosciences and its competitors. Pulse Biosciences's current 12-1 Month Momentum % is 88.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current 12-1 Month Momentum % of 88.26%. The current 12-1 Month Momentum % is 88.26%. Pulse Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current 12-1 Month Momentum % is 88.26% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score
Get the complete analysis for PLSE
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSE has been successfully added to your 
